Zacks Investment Research cut shares of Zafgen (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine lowered shares of Zafgen from a sell rating to a strong sell rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $6.63.
Zafgen (ZFGN) traded down $0.04 during mid-day trading on Friday, hitting $5.56. 111,654 shares of the company were exchanged, compared to its average volume of 155,300. Zafgen has a 12-month low of $3.21 and a 12-month high of $5.75.
Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.12. analysts predict that Zafgen will post -2.02 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the business. OxFORD Asset Management LLP increased its stake in Zafgen by 65.0% in the third quarter. OxFORD Asset Management LLP now owns 171,112 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 67,394 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the second quarter valued at approximately $259,000. 683 Capital Management LLC increased its stake in Zafgen by 8.5% in the third quarter. 683 Capital Management LLC now owns 1,300,000 shares of the biopharmaceutical company’s stock valued at $4,576,000 after purchasing an additional 101,600 shares during the last quarter. Vanguard Group Inc. increased its stake in Zafgen by 15.7% in the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock valued at $3,102,000 after purchasing an additional 119,902 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Zafgen by 31.8% in the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 140,848 shares during the last quarter. Institutional investors own 48.60% of the company’s stock.
WARNING: “Zafgen (ZFGN) Downgraded to Hold at Zacks Investment Research” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/zafgen-zfgn-downgraded-to-hold-at-zacks-investment-research.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.